Hyperhomocysteinemia is an emerging comorbidity in ischemic stroke

Area of Science:

• Neuroscience
• Metabolic Disorders
• Stroke Research

Background:

• Hyperhomocysteinemia (elevated homocysteine) is a known risk factor for ischemic stroke.
• The impact of hyperhomocysteinemia predisposition on stroke severity remains unclear.
• Understanding this link is crucial for developing effective stroke treatments.

Purpose of the Study:

• To review rodent models of hyperhomocysteinemia.
• To assess the effect of mild hyperhomocysteinemia on ischemic brain damage.
• To summarize homocysteine-induced neurotoxicity mechanisms.

Main Methods:

• Analysis of existing literature on rodent models of hyperhomocysteinemia.
• Evaluation of preclinical studies on mild hyperhomocysteinemia and ischemic brain damage.
• Synthesis of research on neurotoxic mechanisms of homocysteine.

Main Results:

• Rodent models offer insights but have limitations for studying hyperhomocysteinemia.
• Mild hyperhomocysteinemia exacerbates ischemic brain damage in preclinical models.
• Homocysteine exerts neurotoxicity through various identified mechanisms.

Conclusions:

• Hyperhomocysteinemia may be a significant comorbidity influencing ischemic stroke severity.
• Findings support considering hyperhomocysteinemia in stroke therapeutic strategies.
• Further research is warranted to translate these findings into clinical practice.